Anti-Covid 19 vaccines may be produced in the Philippines if talks between the government and drug manufacturers succeed.
Filipino pharmaceutical firm Glovax Biotech has partnered with a Korean vaccine manufacturer to produce the EuCorVac-19 in the Philippines, should the government purchase 40 million doses of the Covid-19 vaccine.
Glovax said it is in talks with the Department of Trade and Industry and the Board of Investments for the possible investment for next-generation Covid-19 vaccine production facility.
Should the government order 40 million doses of the vaccine, the company will invest P7 billion for the manufacturing plant and technology transfer cost, said Glovax — the first and only company that brought the vaccine to the country during the AH1N1 swine flu pandemic in 2009 to 2010.
“The local Covid-19 vaccine plant is capable of producing 100 million doses of next-generation Covid-19 vaccine annually and could help in alleviating our burden of waiting for other countries’ excess supply,” Glovax added.
The company said National Task Force Against Covid-19 chief implementer and vaccine czar Carlito Galvez Jr. has endorsed Glovax to the Department of Science and Technology.
The pharma firm will be partnering with Korean firm Eubiologics to locally produce EuCorVac-19, which was developed in the United States by POP Biotechnologies.